Aficamten Significantly Improves Exercise Capacity and Symptoms in Patients with Obstructive Hypertrophic Cardiomyopathy: Results from the Phase 3 SEQUOIA-HCM Trial
In a groundbreaking development for the treatment of obstructive hypertrophic cardiomyopathy (oHCM), the Phase 3 SEQUOIA-HCM trial has demonstrated that